in vitro News and Research

RSS

New study: Egg donors may be paid too much

"Women who donate eggs for use with in-vitro techniques aren't supposed to be compensated more than $10,000 .... according to guidelines from the American Society of Reproductive Medicine," The Wall Street Journal reports.

26 Mar 2010

VisEn Medical announces launch of new GastroSense 750 fluorescence agent for imaging gastric motility

VisEn Medical Inc., a leader in fluorescence imaging from research through medicine, announced today the commercial launch of its new GastroSense™ 750 fluorescence agent for imaging gastric motility and related drug effects in vivo.

26 Mar 2010

Fertility industry offers big money to recruit “desirable” egg donors at top universities

Many egg donation agencies and private couples routinely exceed compensation recommendation limits for potential donors, a new study finds.

25 Mar 2010

Tips offered in April 2010 issue of American Journal Of Pathology

A group led by Dr. Massimo Loda at the Dana Farber Cancer Institute, Boston, MA has generated a preclinical model of human prostate cancer that mimics the genetic and growth behavior of primary tumors. Their report can be found in the April 2010 issue of the American Journal of Pathology.

25 Mar 2010

Majority of egg donation agencies violate ASRM guidelines

From a sample of over 300 college newspapers, findings revealed that almost one-quarter of advertisements offered payment in excess of $10,000, a violation of guidelines issued by the American Society for Reproductive Medicine (ASRM).

25 Mar 2010

Life Technologies' real-time PCR instrument available for IVD use in Europe

Life Technologies Corporation (NASDAQ: LIFE) today announced that its Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument is available as a platform suitable for in vitro diagnostics (IVD) use in Europe. Clinical laboratories from 22 countries and European institutions that develop in vitro molecular diagnostic assays in oncology, genetic disease and infectious disease will now be able to leverage the instrument’s regulatory clearance to develop tests for clinical applications.

24 Mar 2010

Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases

Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.

23 Mar 2010

New research at Tel Aviv University may lay groundwork for retinal implants in people

Television's Six Million Dollar Man foresaw a future when man and machine would become one. New research at Tel Aviv University is making this futuristic "vision" of bionics a reality.

23 Mar 2010

FDA's ODAC voted to review T315I mutation prior to approval of OMAPRO

ChemGenex Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee voted 7-1 that a validated test to identify the T315I mutation should be reviewed by the FDA prior to approval of OMAPRO™ (omacetaxine mepesuccinate).

23 Mar 2010

Researchers develop new compound to inhibit HIV transmission

A compound that can inhibit the transfer of HIV from one cell to another has been developed by researchers at the Institut de Biologie Structurale Jean-Pierre Ebel.

22 Mar 2010

Aston University scientists receive grants to develop new forms of drug delivery

Before you swallow a tablet, or put it into a glass of water to dissolve, do you ever stop and think about how it actually works in your body and how quickly and effectively it can deliver the drug to where it is needed?

22 Mar 2010

EUREKA project develops unique range of antibodies

EUREKA project E! 3424 RECAN has developed a range of unique and highly specific monoclonal and polyclonal antibodies - the proteins produced in the blood which counteract bacteria, viruses or cancerous cells.

20 Mar 2010

Mini-laboratory: IVD platform to be presented at Analytica trade show

Many illnesses can be reliably diagnosed through laboratory tests, but these in vitro analyses often use up valuable time. A system developed by Fraunhofer research scientists, which can carry out complex analyses on the spot, will soon be ready for the market.

19 Mar 2010

Achillion Pharmaceuticals receives NIH SBIR grant for study of novel antibacterial compound series

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that it has received a Phase 1 Small Business Innovation Research Grant (SBIR) from the National Institute of Allergy and Infectious Disease (NIAID) branch of the National Institutes of Health (NIH) for the further study and characterization of a back-up series of compounds related to its novel antibacterial, ACH-702.

18 Mar 2010

Studies link atmospheric CO pollution to adverse cardiovascular outcomes, cardiac mortality

In the healthy rat, prolonged exposure to carbon monoxide (CO) under conditions that mimic urban pollution leads to changes to cardiac morphology and function. Compensatory mechanisms develop in these animals to sustain normal cardiac activity, but they become more vulnerable to heart disease.

18 Mar 2010

Toxins released by certain microalgae can contaminate seafood and become toxic to humans

Toxins released by certain microalgae can contaminate fish and shellfish which then become toxic to humans. Researchers from CNRS and CEA have, for the first time, identified the mechanisms of action of two of these toxins.

18 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark Office covering technology relating to monoclonal antibodies that bind to certain epitopes present on pancreatic cancers. This patent will broaden the Company’s proprietary intellectual property for ICT-109 and ICT-37, two of the Company’s monoclonal antibody product candidates.

17 Mar 2010

Full Medicare coverage for IVF: CFAS felicitates Quebec government

The Canadian Fertility and Andrology Society (CFAS) congratulates Premier Jean Charest and his Government on their announcement of full Medicare coverage for in-vitro fertilization treatments in Quebec.

17 Mar 2010

Compugen announces validation of IDD discovery platform for identification of cell penetrating peptides

Compugen Ltd. announced today the development and validation of its Intracellular Drug Delivery (IDD) discovery platform for identification of cell penetrating peptides. Compugen also announced that as part of the validation process for the new platform, more than twenty novel peptides, predicted and selected in silico, demonstrated the predicted cell penetrating properties in initial experimental validation studies.

17 Mar 2010

Human amniotic fluid skin cells "reprogrammed" to pluripotency

In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body. The study is online now and will appear in print in the next issue of the journal Cellular Reprogramming, to be published next month.

16 Mar 2010

in vitro News and Research

New study: Egg donors may be paid too much

VisEn Medical announces launch of new GastroSense 750 fluorescence agent for imaging gastric motility

Fertility industry offers big money to recruit “desirable” egg donors at top universities

Tips offered in April 2010 issue of American Journal Of Pathology

Majority of egg donation agencies violate ASRM guidelines

Life Technologies' real-time PCR instrument available for IVD use in Europe

Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases

New research at Tel Aviv University may lay groundwork for retinal implants in people

FDA's ODAC voted to review T315I mutation prior to approval of OMAPRO

Researchers develop new compound to inhibit HIV transmission

Aston University scientists receive grants to develop new forms of drug delivery

EUREKA project develops unique range of antibodies

Mini-laboratory: IVD platform to be presented at Analytica trade show

Achillion Pharmaceuticals receives NIH SBIR grant for study of novel antibacterial compound series

Studies link atmospheric CO pollution to adverse cardiovascular outcomes, cardiac mortality

Toxins released by certain microalgae can contaminate seafood and become toxic to humans

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

Full Medicare coverage for IVF: CFAS felicitates Quebec government

Compugen announces validation of IDD discovery platform for identification of cell penetrating peptides

Human amniotic fluid skin cells "reprogrammed" to pluripotency

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News